64187-48-0

Basic information

• Product Name: Z-HYP-OME
• Synonyms: N-Cbz-trans-4-hydroxy-L-proline methyl ester;Z-O-tert-Butyl-L-4-hydroxyproline;(2S,4R)-1-(Benzyloxycarbonyl)-2-(methoxycarbonyl)-4-hydroxypyrrolidine;(2S,4R)-1-Benzyloxycarbonyl-4-hydroxypyrrolidin-2-carboxylic acid methyl ester;1-Benzyl 2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate;N-(Benzyloxycarbonyl)-4-hydroxyproline methyl ester;(2S,4R)-1-benzyl 2-Methyl 4-hydro×ypyrrolidine-1,2-dicarbo×ylate;N-Benzyloxycarbonyl-4-trans-hydroxy-L-proline Methyl ester, 98%
• CAS NO: 64187-48-0
• Molecular Formula: C₁₄H₁₇NO₅
• Molecular Weight: 279.29
• EINECS: 236-831-2
• Mol File: 64187-48-0.mol
• Article Data: 62

Chemical Properties

• Boiling Point: 422.779 °C at 760 mmHg
• Flash Point: 209.49 °C
• Appearance: Pale yellow/viscous liquid
• Density: 1.313
• Vapor Pressure: 6.67E-08mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: −20°C
• PKA: 14.25±0.40(Predicted)
• CAS DataBase Reference: Z-HYP-OME(CAS DataBase Reference)
• NIST Chemistry Reference: Z-HYP-OME(64187-48-0)
• EPA Substance Registry System: Z-HYP-OME(64187-48-0)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 64187-48-0(Hazardous Substances Data)

Usage

Uses

N-(Benzyloxycarbonyl)-4-hydroxyproline Methyl Ester, can be used as an intermediate in the synthesis of various pharmaceutical and biologically active compounds. It is used in the synthesis of Doripenem (D534800), an Antibacterial agent.

InChI:InChI=1/C14H17NO5/c1-19-13(17)12-7-11(16)8-15(12)14(18)20-9-10-5-3-2-4-6-10/h2-6,11-12,16H,7-9H2,1H3/t11-,12+/m1/s1

Upstream product

• 67-56-1 methanol 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 618-28-0 trans-4-hydroxy-D,L-proline 
• 51-35-4 4R-4-hydroxyproline 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 16217-15-5 1-benzyloxycarbonyl-4-oxo-L-proline methyl ester 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 124-41-4 sodium methylate 
• 13500-53-3 N-benzyloxycarbonyl-(2S,4R)-4-hydroxyproline benzyl ester 

Downstream Products

• 170159-62-3 (2S,4S)-N-benzyloxycarbonyl-4-formyloxyproline methyl ester 
• 122350-62-3 (2S,4R)-4-((2R,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 122350-62-3 (2S,4R)-4-((2S,3R,4S,5R,6R)-3,4,5-Triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 72180-14-4 N-<(phenylmethoxy)carbonyl>-4(S)-fluoro-(S)-proline methyl ester 
• 146951-99-7 (2S,4R)-1-(Benzyloxycarbonyl)-4-(tert-butyloxy)-2-pyrrolidincarbonsaeure-methylester 
• 57653-38-0 N-<(phenylmethoxy)carbonyl>-4(R)-<<(4-methylphenyl)sulfonyl>oxy>-(S)-proline methyl ester 
• 115545-74-9 Cbz-4-(2-cyanoethyl)-Pro-OMe 
• 117811-78-6 methyl (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylate 
• 128359-96-6 (2S,4S)-4-acetoxy-1,2-pyrrolidinedicarboxylic acid 2-methyl 1-phenylmethyl diester 
• 114358-14-4 O₁-benzyl O₂-methyl (2S,4R)-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1,2-dicarboxylate 
• 146952-00-3 (2S,4R)-1-(Benzyloxycarbonyl)-4--2-pyrrolidincarbonsaeure-methylester 
• 126111-26-0 trans-4-(2,2-dimethyl-1-oxopropoxy)-1-<(phenylmethoxy)carbonyl>-L-proline methyl ester 
• 199998-81-7 (2S,4R)-1-benzyloxycarbonyl-2-{2-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-2-oxoethyl}-oxymethyl-4-methanesulfonyloxypyrrolidine 
• 127768-10-9 (2S,4R)-1-benzyloxycarbonyl-2-[{3-[ethoxycarbonyl)-2-propenyl}oxymethyl]-4-methanesulfonyloxypyrrolidine 

Relevant articles and documents

ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

NOVEL SALT OF 4-({(4S)-1-(4-CARBAMIMIDOYLBENZOYL)-4-[4(METHYLSULFONYL)PIPERAZIN-1-YL]-L-PROLYL}AMINO) BENZOIC ACID AND NOVEL CRYSTAL FORM THEREOF

4-({(4S)-1-(4-Carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-L-prolyl}amino) benzoic acid di(4-toluenesulfonate) or dibenzenesulfonate or their crystal forms can be useful pharmaceutical ingredients because of their low hygroscopicity and excellent storage stability.

Practical Gram-Scale Synthesis of Iboxamycin, a Potent Antibiotic Candidate

A gram-scale synthesis of iboxamycin, an antibiotic candidate bearing a fused bicyclic amino acid residue, is presented. A pivotal transformation in the route involves an intramolecular hydrosilylation-oxidation sequence to set the ring-fusion stereocenters of the bicyclic scaffold. Other notable features of the synthesis include a high-yielding, highly diastereoselective alkylation of a pseudoephenamine amide, a convergent sp3-sp2 Negishi coupling, and a one-pot transacetalization-reduction reaction to form the target compound's oxepane ring. Implementation of this synthetic strategy has provided ample quantities of iboxamycin to allow for its in vivo profiling in murine models of infection.